AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Patients with BRCA mutations often face aggressive disease and poor prognosis
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Subscribe To Our Newsletter & Stay Updated